Evidence map›Paper›PMID 26531896›Full record

ArticleScientific reports2015

IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance.

Yi-Fan Lu, David M Mauger, David B Goldstein, Thomas J Urban, Kevin M Weeks, Shelton S Bradrick

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Innate Immunity in Hepatitis C Virus Infection.Cold Spring Harbor perspectives in medicine · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Genetics of the Human Interferon Lambda Region.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yi-Fan LuDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham NC, 27710, USA.
David M MaugerDepartment of Chemistry, University of North Carolina, Chapel Hill, NC 27599-3290, USA.
David B GoldsteinInstitute for Genomic Medicine, Columbia University, New York, NY 10032, USA.
Thomas J UrbanCenter for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7361, USA.
Kevin M WeeksDepartment of Chemistry, University of North Carolina, Chapel Hill, NC 27599-3290, USA.
Shelton S BradrickDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham NC, 27710, USA.
University of North Carolina at Chapel Hill · USColumbia University · USDuke University Hospital · USThe University of Texas Medical Branch at Galveston · US

Funding

Integrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7M
Discovery and development of broad spectrum anti-flaviviral drugsR01AI089526 · NIAID · DUKE UNIVERSITY · PI ENGEL, DANIEL A, GARCIA-BLANCO, MARIANO A. · 2010 to 2014
$4.1M
Retroviral Genomic RNA Dimer Structure and FunctionR01GM064803 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WEEKS, KEVIN M · 2002 to 2016
$3.7M
Host-pathogen interactions in hepatitis C virus replicationK01DK082613 · NIDDK · DUKE UNIVERSITY · PI BRADRICK, SHELTON STEWART · 2009 to 2013
$546k
NCI NIH HHS T32 CA009156NCI NIH HHS T32CA009156NIAID NIH HHS AI089526NIAID NIH HHS R01 AI089526NIDDK NIH HHS DK826135NIDDK NIH HHS K01 DK082613NIGMS NIH HHS GM064803NIGMS NIH HHS R01 GM064803
6 · The paper itself

Abstract

Polymorphisms near the interferon lambda 3 (IFNL3) gene strongly predict clearance of hepatitis C virus (HCV) infection. We analyzed a variant (rs4803217 G/T) located within the IFNL3 mRNA 3' untranslated region (UTR); the G allele (protective allele) is associated with elevated therapeutic HCV clearance. We show that the IFNL3 3' UTR represses mRNA translation and the rs4803217 allele modulates the extent of translational regulation. We analyzed the structures of IFNL3 variant mRNAs at nucleotide resolution by SHAPE-MaP. The rs4803217 G allele mRNA forms well-defined 3' UTR structure while the T allele mRNA is more dynamic. The observed differences between alleles are among the largest possible RNA structural alterations that can be induced by a single nucleotide change and transform the UTR from a single well-defined conformation to one with multiple dynamic interconverting structures. These data illustrate that non-coding genetic variants can have significant functional effects by impacting RNA structure.

Indexed as

3' Untranslated RegionsAntiviral AgentsCell Line, TumorGene Expression RegulationGenetic Predisposition to DiseaseHeLa CellsHepacivirusHepatitis C, ChronicHumansInterferon LambdaInterferonsInterleukinsPolymorphism, Single NucleotideRNA, Messenger3' Untranslated RegionsAntiviral AgentsInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsRNA, Messenger

Identifiers

PMID26531896
PMCPMC4631997
OpenAlexW2418971489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.